RT Journal Article
SR Electronic
T1 Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21257070
DO 10.1101/2021.05.13.21257070
A1 Schmaier, Alec A.
A1 Hurtado, Gabriel Pajares
A1 Manickas-Hill, Zachary J.
A1 Sack, Kelsey D.
A1 Chen, Siyu M
A1 Bhambhani, Victoria
A1 Quadir, Juweria
A1 Nath, Anjali K.
A1 Collier, Ai-ris Y.
A1 Ngo, Debby
A1 Barouch, Dan H.
A1 Gerszten, Robert E.
A1 Yu, Xu G.
A1 ,
A1 Peters, Kevin
A1 Flaumenhaft, Robert
A1 Parikh, Samir M.
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.13.21257070.abstract
AB Profound endothelial dysfunction accompanies the microvascular thrombosis commonly observed in severe COVID-19. In the quiescent state, the endothelial surface is anticoagulant, a property maintained at least in part via constitutive signaling through the Tie2 receptor. During inflammation, the Tie2 antagonist angiopoietin-2 (Angpt-2) is released from activated endothelial cells and inhibits Tie2, promoting a prothrombotic phenotypic shift. We sought to assess whether severe COVID-19 is associated with procoagulant dysfunction of the endothelium and alterations in the Tie2-angiopoietin axis. Primary human endothelial cells treated with plasma from patients with severe COVID-19 upregulated the expression of thromboinflammatory genes, inhibited expression of antithrombotic genes, and promoted coagulation on the endothelial surface. Pharmacologic activation of Tie2 with the small molecule AKB-9778 reversed the prothrombotic state induced by COVID-19 plasma in primary endothelial cells. On lung autopsy specimens from COVID-19 patients, we found a prothrombotic endothelial signature as evidenced by increased von Willebrand Factor and loss of anticoagulant proteins. Assessment of circulating endothelial markers in a cohort of 98 patients with mild, moderate, or severe COVID-19 revealed profound endothelial dysfunction indicative of a prothrombotic state. Angpt-2 concentrations rose with increasing disease severity and highest levels were associated with worse survival. These data highlight the disruption of Tie2-angiopoietin signaling and procoagulant changes in endothelial cells in severe COVID-19. Moreover, our findings provide novel rationale for current trials of Tie2 activating therapy with AKB-9778 in severe COVID-19 disease.Competing Interest StatementSamir M Parikh serves on the advisory board for Aerpio Pharmaceuticals. Kevin Peters is an employee of Aerpio pharmaceuticals.Funding StatementFunding for this project was supported by a grant from the Massachusetts Consortium for Pathogen Readiness Evergrande COVID-19 Response Fund (AAS, RF, SMP), the North American Thrombosis Forum COVID-19 Research Initiative (AAS), and grants from the NIH (R35-HL139424, SMP). The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness and the Ragon Institute of MGH, MIT and Harvard.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study measuring biomarkers and associated clinical data in patients enrolled in the BIDMC COVID-19 Data and Tissue Repository was approved by the BIDMC IRB (protocols 2020P000621). For all COVID-19 autopsy studies, patients were consented for limited autopsies by a pathologist during a witnessed phone call immediately after death of the patient. Research using autopsy tissue was approved by the BIDMC institutional review board (IRB 2020P000525). A HIPPA waiver was granted to access the medical records of the patients undergoing autopsy (IRB 2020P00412).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are no datasets to deposit. Other data will be made available upon request via correspondence with the authors.